Imagine a world where an HIV prevention method lasts for six months, offering protection without the daily hassle of taking a ...

This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled ...

Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...

Failure to ensure that everyone has access to prevention options to protect oneself from HIV acquisition, has resulted in at ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the ...

New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...

Former U.K. foreign aid officials' advice to Prime Minister Keir Starmer. Plus time is running out for the U.N.'s “failing ...

Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead has been testing it as an injectable form ...

Lenacapavir, a bi-annual injectable treatment for HIV prevention (PrEP), is being celebrated as a major advancement in the ...

The generic companies that will manufacture and supply Lenacapavir to 120 countries are Dr. Reddy’s, Emcure, Eva Pharma, ...

The world’s first woman-controlled HIV prevention product, the dapivirine vaginal ring (DVR), has been approved for use in 11 African countries. This move signalled a significant advancement in the ...